MGTX · Insider Trading
MeiraGTx Holdings plc Ordinary Shares
Every open-market purchase and sale reported by MGTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-20 | Richard Giroux | CFO & COO | Sell | −56,000 | −$557.20K |
| 2026-10-06 | Stuart Naylor | CHIEF SCI OFCR, OPHTHALMOLOGY | Sell | −27,659 | −$294.29K |
| 2026-09-24 | Alan Sebulsky | Director | A | +100,000 deriv. | — |
| 2026-08-18 | Alexandria Forbes | PRESIDENT & CEO | Sell | −62,000 | −$859.32K |
| 2026-07-21 | Richard Giroux | CFO & COO | Sell | −56,000 | −$700.56K |
| 2026-07-07 | Stuart Naylor | CHIEF SCI OFCR, OPHTHALMOLOGY | Sell | −27,659 | −$409.47K |
| 2026-06-29 | Robert J Wollin | GENERAL COUNSEL AND SECRETARY | A | +100,000 deriv. | — |
| 2026-06-29 | Alexandria Forbes | PRESIDENT & CEO | A | +980,000 deriv. | — |
| 2026-06-29 | Robert K Zeldin | CHIEF MEDICAL OFFICER | A | +100,000 deriv. | — |
| 2026-06-29 | Richard Giroux | CFO & COO | A | +980,000 deriv. | — |
| 2026-06-29 | Stuart Naylor | CHIEF SCI OFCR, OPHTHALMOLOGY | A | +70,000 deriv. | — |
| 2026-06-15 | Keith R. Harris | Director | A | +106,441 deriv. | — |
| 2026-06-15 | Neil Mendoza | Director | A | +66,641 deriv. | — |
| 2026-06-15 | Nicole Seligman | Director | A | +60,000 deriv. | — |
| 2026-06-15 | Ellen Hukkelhoven | Director | A | +60,000 deriv. | — |
| 2026-06-15 | Debra Yu | Director | A | +60,000 deriv. | — |
| 2026-06-15 | PERCEPTIVE ADVISORS LLC | Director | A | +180,000 deriv. | — |
| 2026-06-15 | Thomas E Shenk | Director | A | +69,662 deriv. | — |
| 2026-06-10 | Keith R. Harris | Director | M | +75,000 | — |
| 2026-05-28 | Richard Giroux | CFO & COO | G | −7,000 | — |
| 2026-05-19 | Alexandria Forbes | PRESIDENT & CEO | Sell | −62,000 | −$568.54K |
| 2026-05-14 | Penny Renee Fleck | CHIEF DEVELOPMENT OFFICER | A | +200,000 deriv. | — |
| 2026-04-28 | Robert K Zeldin | CHIEF MEDICAL OFFICER | F | −7,814 | −$60.40K |
| 2026-04-23 | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director | A | +1,666,665 | +$15.00M |
| 2026-04-21 | Richard Giroux | CFO & COO | Sell | −56,000 | −$572.32K |
| 2026-04-07 | Stuart Naylor | CHIEF DEV. OFFICER | Sell | −27,661 | −$258.91K |
| 2026-03-24 | Alexandria Forbes | PRESIDENT & CEO | Sell | −62,000 | −$459.42K |
| 2026-02-23 | Robert K Zeldin | CHIEF MEDICAL OFFICER | MIXED | +4,548 | −$21.99K |
| 2026-02-23 | Stuart Naylor | CHIEF DEV. OFFICER | MIXED | +13,250 | −$87.54K |
| 2026-02-23 | Richard Giroux | CFO & COO | MIXED | +28,274 | −$236.36K |
| 2026-02-23 | Robert J Wollin | GENERAL COUNSEL AND SECRETARY | MIXED | +5,301 | −$44.32K |
| 2026-02-23 | Alexandria Forbes | PRESIDENT & CEO | MIXED | +29,452 | −$246.21K |
| 2026-01-21 | Stuart Naylor | CHIEF DEV. OFFICER | MIXED | +39,750 | −$261.56K |
| 2026-01-21 | Richard Giroux | CFO & COO | MIXED | +146,084 | −$1.22M |
| 2026-01-21 | Alexandria Forbes | PRESIDENT & CEO | MIXED | +146,084 | −$1.22M |
| 2026-01-21 | Robert J Wollin | GENERAL COUNSEL AND SECRETARY | MIXED | +22,794 | −$201.87K |
| 2026-01-21 | Robert K Zeldin | CHIEF MEDICAL OFFICER | MIXED | +21,049 | −$103.52K |
| 2026-01-08 | Robert J Wollin | GENERAL COUNSEL AND SECRETARY | MIXED | +3,136 | −$33.73K |
| 2026-01-08 | Robert K Zeldin | CHIEF MEDICAL OFFICER | MIXED | +10,771 | −$52.02K |
| 2026-01-08 | Stuart Naylor | CHIEF DEV. OFFICER | MIXED | +19,875 | −$136.24K |
| 2026-01-08 | Alexandria Forbes | PRESIDENT & CEO | MIXED | +28,426 | −$263.39K |
| 2026-01-08 | Richard Giroux | CFO & COO | MIXED | +23,678 | −$222.79K |
| 2026-01-02 | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director | D | −6,900,000 | −$54.58M |
| 2025-12-23 | Alexandria Forbes | PRESIDENT & CEO | G | −6,250 | — |
| 2025-11-24 | Robert J Wollin | GENERAL COUNSEL AND SECRETARY | G | −5,000 | — |
| 2025-10-21 | Richard Giroux | CFO & COO | Sell | −24,000 | −$212.88K |
| 2025-10-07 | Alexandria Forbes | PRESIDENT & CEO | Sell | −47,500 | −$398.52K |
| 2025-07-22 | Richard Giroux | CFO & COO | Sell | −24,000 | −$204.48K |
| 2025-07-08 | Alexandria Forbes | PRESIDENT & CEO | Sell | −47,500 | −$378.57K |
| 2025-07-02 | Richard Giroux | CFO & COO | G | −5,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | Director | 11,281,103 | $103.90M |
| PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director | 10,786,658 | $99.35M |
| Alexandria Forbes | PRESIDENT & CEO | 1,354,680 | $12.48M |
| Richard Giroux | CFO & COO | 937,530 | $8.63M |
| Stuart Naylor | CHIEF SCI OFCR, OPHTHALMOLOGY | 613,187 | $5.65M |
| Keith R. Harris | Director | 200,000 | $1.84M |
| Thomas E Shenk | Director | 157,476 | $1.45M |
| Robert K Zeldin | CHIEF MEDICAL OFFICER | 146,204 | $1.35M |
| Robert J Wollin | GENERAL COUNSEL AND SECRETARY | 57,377 | $528.44K |
| Nicole Seligman | Director | 5,000 | $46.05K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MGTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.